FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

The U.S. Food and Drug Administration (FDA) on Monday approved Krystal Biotech, Inc.’s KRYS label update for Vyjuvek (beremagene geperpavec-svdt).The update expands the Vyjuvek eligible patient population to include dystrophic epidermolysis bullosa (DEB) patients from birth and provides patients full flexibility with respect to Vyjuvek application and managing wound dressings.Epidermolysis bullosa (EB) is a group of rare, inherited genetic conditions that cause the skin and mucous membranes to be fragile, l ...